Tocagen Inc (TOCA) Upgraded by Zacks Investment Research to “Hold”
Tocagen Inc (NASDAQ:TOCA) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday.
According to Zacks, “Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company which focuses on retroviral gene therapy platforms. The company’s lead product candidate consists of Toca 511 & Toca FC, initially for the treatment of recurrent high grade glioma, a disease with a significant unmet medical need. Tocagen, Inc. is based in San Diego, United States. “
Separately, Stifel Nicolaus reiterated a “buy” rating and issued a $24.00 target price on shares of Tocagen in a report on Tuesday, July 25th.
Shares of Tocagen (TOCA) traded down 0.59% on Wednesday, hitting $10.18. 35,186 shares of the stock were exchanged. The company’s market cap is $201.66 million. The firm’s 50-day moving average is $12.52 and its 200-day moving average is $13.21. Tocagen has a one year low of $9.68 and a one year high of $17.95.
Tocagen (NASDAQ:TOCA) last released its earnings results on Wednesday, August 9th. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.04). The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.01 million. On average, equities analysts forecast that Tocagen will post ($2.51) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/11/tocagen-inc-toca-upgraded-by-zacks-investment-research-to-hold-2.html.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. New York State Common Retirement Fund bought a new stake in shares of Tocagen in the 2nd quarter worth approximately $108,000. TD Asset Management Inc. bought a new stake in shares of Tocagen in the 2nd quarter worth approximately $158,000. Schwab Charles Investment Management Inc. bought a new stake in shares of Tocagen in the 2nd quarter worth approximately $165,000. California State Teachers Retirement System bought a new stake in shares of Tocagen in the 2nd quarter worth approximately $179,000. Finally, Teachers Advisors LLC bought a new stake in shares of Tocagen in the 2nd quarter worth approximately $181,000. Institutional investors and hedge funds own 37.87% of the company’s stock.
Tocagen Company Profile
Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tocagen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen Inc and related companies with MarketBeat.com's FREE daily email newsletter.